Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Effect of pemafibrate in reducing intestinal long-chain fatty acid absorption and hepatic fibrosis in metabolic dysfunction-associated steatohepatitis rats

Fig. 3

Pemafibrate improves liver fibrosis. (a) Liver sections from the pemafibrate (-) and pemafibrate (+) groups. Sirius Red staining. Magnification, 200×. Scale bar: 100 μm. (b) Area of Sirius red staining in the livers of rats from the pemafibrate (-) and pemafibrate (+) groups. N = 5 per group; *P < 0.05. (c) Liver sections of rats from the pemafibrate (-) and pemafibrate (+) groups. Anti-α-SMA antibody. Magnification, 200×. Scale bar: 100 μm. (d) Area of anti-α-SMA antibody in the livers of rats from the pemafibrate (-) and pemafibrate (+) groups. N = 5 per group; *P < 0.05. Data in the bar plots are expressed as mean ± standard deviation. Significant differences were determined using the Mann–Whitney U-test

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us